Neuphoria Therapeutics (NEUP) Retained Earnings (2021 - 2026)
Neuphoria Therapeutics (NEUP) reported Retained Earnings of -$2.1 million for Q1 2026, up 98.78% year-over-year from -$1.0 million in Q1 2025, and up 98.89% on a QoQ basis from -$186.4 million in Q4 2025.
Neuphoria Therapeutics (NEUP) has 6 years of Retained Earnings data on file, last reported at -$2.1 million in Q1 2026.
- Quarterly Retained Earnings rose 98.78% year-over-year to -$2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.1 million (up 98.78% YoY) and the FY2025 annual result came in at -$2.8 million, up 98.4% from the prior year.
- Retained Earnings climbed to -$2.1 million in Q1 2026 per NEUP's latest filing, from -$186.4 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$2.1 million in Q1 2026 and bottomed at -$188.3 million in Q3 2025.
- The 5-year median for Retained Earnings is -$153.2 million (2023), against an average of -$117.1 million.
- The widest annual swing landed in 2025, when Retained Earnings plunged 4888.42%; it then jumped 98.78% in 2026.
- Tracing NEUP's Retained Earnings over 5 years: stood at -$124.1 million in 2022, then declined by 10.25% to -$136.9 million in 2023, then surged by 97.27% to -$3.7 million in 2024, then sank by 4888.42% to -$186.4 million in 2025, then surged by 98.89% to -$2.1 million in 2026.
- Per Business Quant, the three latest NEUP Retained Earnings figures stand at -$2.1 million (Q1 2026), -$186.4 million (Q4 2025), and -$188.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | -2.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.07 Mn |
| Dec 31, 2025 | -186.40 Mn |
| Sep 30, 2025 | -188.30 Mn |
| Jun 30, 2025 | -178.35 Mn |
| Mar 31, 2025 | -3.91 Mn |
| Dec 31, 2024 | -3.74 Mn |
| Sep 30, 2024 | -178.78 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Jun 30, 2023 | -136.86 Mn |
| Jun 30, 2022 | 8.97 Mn |
| Dec 31, 2021 | -119.98 Mn |
| Jun 30, 2021 | -118.62 Mn |